The Administrative Core will oversee and monitor all aspects ofthe Program. Dr. White, as PI, will interact on a weekly (minimally), often daily, basis with the other Project Pls, including Drs. Day and Aganwal. He will meet daily with Ms. Cheatham to discuss all pressing matters regarding the program, including upcoming CounterACT meetings, progress reports, interactive meetings with collaborators, meetings of the Internal (lAC) and External Advisory Committees (EAC), implementation of any new directives/mandates from NIH program staff, development of new scientific initiatives within the program as a result of lAC and or EAC recommendations, preparation of responses to EAC recommendations, monitoring of the program's CounterACT website, monitoring the training and progress of sponsored pre-doctoral, postdoctoral, and junior faculty involved in the program in Denver and at collaborating sites. Likewise, he will make decisions and take actions to respond to any of these matters and any other upcoming deadlines relevant to the program. He will be involved, along with Drs. Day and Aganwal, in recmiting new personnel among academic trainees and technical staff. He will coordinate and facilitate collaborative interactions between the projects in Denver and with the offsite collaborators, and he will initiate new offsite collaborations as required by new scientific directions and recommendations by the EAC and NIH administrative staff. He will write and submit grant supplements and, if available, carry fonward requests in order to allow success towards these mandates. He will oversee the Quality Assurance program throughout the Denver CounterACT group, and, in particular, monitor progress of each Project towards its timely achievement of its milestones and the quality of the data documenting that progress. Finally, he will convene regular meetings ofthe project Pls and their trainees to discuss scientific progress. He will assist all members of the team in their preparation of presentations and posters for the annual CounterACT meeting and all regional and national scientific meetings where CounterACT program findings will be presented. He will also interact regularly with Dr. Robert Mason to discuss potential regular guest speakers in the biodefense area and to prepare an annual symposium day on chemical defense and biodefense for the Denver area. Finally, he will oversee industry interactions of the program, including regular review of agents showing potential for rescue of injury due to mustard and/or chlorine and their product development. He will interact with industry partners to try to assure continued progress toward development of products after they have left the pre-clinical arena of the proof-of-principle studies routinely included in the CounterACT program. These would include presentations to, and applications for, BARDA, DTRA, and other DoD-sponsored grants for GLP studies and eventual FDA approval. All of the above-described activities have been among the daily, or at least regular, activities of the Administrative Core during the last cycle.

National Institute of Health (NIH)
National Institute of Environmental Health Sciences (NIEHS)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-MDCN-J (54))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Jewish Health
United States
Zip Code
Rancourt, Raymond C; Rioux, Jacqueline S; Veress, Livia A et al. (2018) Methyl isocyanate inhalation induces tissue factor-dependent activation of coagulation in rats. Drug Chem Toxicol :1-7
Summerhill, Eleanor M; Hoyle, Gary W; Jordt, Sven-Eric et al. (2017) An Official American Thoracic Society Workshop Report: Chemical Inhalational Disasters. Biology of Lung Injury, Development of Novel Therapeutics, and Medical Preparedness. Ann Am Thorac Soc 14:1060-1072
Ghosh, Moumita; Ahmad, Shama; White, Carl W et al. (2017) Transplantation of Airway Epithelial Stem/Progenitor Cells: A Future for Cell-Based Therapy. Am J Respir Cell Mol Biol 56:1-10
McGraw, Matthew D; Osborne, Christopher M; Mastej, Emily J et al. (2017) Editor's Highlight: Pulmonary Vascular Thrombosis in Rats Exposed to Inhaled Sulfur Mustard. Toxicol Sci 159:461-469
McElroy, Cameron S; Min, Elysia; Huang, Jie et al. (2016) From the Cover: Catalytic Antioxidant Rescue of Inhaled Sulfur Mustard Toxicity. Toxicol Sci 154:341-353
White, Carl W; Rancourt, Raymond C; Veress, Livia A (2016) Sulfur mustard inhalation: mechanisms of injury, alteration of coagulation, and fibrinolytic therapy. Ann N Y Acad Sci 1378:87-95
Tewari-Singh, Neera; Agarwal, Rajesh (2016) Mustard vesicating agent-induced toxicity in the skin tissue and silibinin as a potential countermeasure. Ann N Y Acad Sci 1374:184-92
McElroy, Cameron S; Day, Brian J (2016) Antioxidants as potential medical countermeasures for chemical warfare agents and toxic industrial chemicals. Biochem Pharmacol 100:1-11
Houin, Paul R; Veress, Livia A; Rancourt, Raymond C et al. (2015) Intratracheal heparin improves plastic bronchitis due to sulfur mustard analog. Pediatr Pulmonol 50:118-26
Veress, Livia A; Anderson, Dana R; Hendry-Hofer, Tara B et al. (2015) Airway tissue plasminogen activator prevents acute mortality due to lethal sulfur mustard inhalation. Toxicol Sci 143:178-84

Showing the most recent 10 out of 58 publications